google-site-verification: googlec7193c3de77668c9.html

Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks

[
New results from the Phase III SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes. The findings were published in The Lancet Respiratory Medicine.


Source link

Advertisements

See also  Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain

Check Also

DR Congo’s worst Ebola epidemic ever passes 7,000 cases

[ Credit: Unsplash/CC0 Public Domain More than 7,000 Ebola cases have been recorded in the …

Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer

[ Credit: Pixabay/CC0 Public Domain Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically …

Trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer

[ Credit: Pixabay/CC0 Public Domain Results from the randomized Phase III ARTEMIS-008 trial show that …

Leave a Reply

Available for Amazon Prime